Serina Therapeutics宣布,美国食品药品监督管理局的反馈意见支持其Ser-252药物针对晚期帕金森病的注册试验设计,该试验将通过505(B)(2)新药申请路径进行推进。
Serina Therapeutics宣布,美国食品药品监督管理局的反馈意见支持其Ser-252药物针对晚期帕金森病的注册试验设计,该试验将通过505(B)(2)新药申请路径进行推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.